Question reference: S6W-23194
- Asked by: Alexander Burnett, MSP for Aberdeenshire West, Scottish Conservative and Unionist Party
- Date lodged: 24 November 2023
-
Current status: Answered by Jenni Minto on 11 December 2023
Question
To ask the Scottish Government what discussions it has had regarding modulator therapies to treat cystic fibrosis, such as Orkambi, Symkevi and Kaftrio, being funded on the NHS.
Answer
I refer the member to the answer to question S6W-22774 on 21 November 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
The other two medicines alluded to in that answer are Orkambi ® , and Symkevi ® .
If any cystic fibrosis medicine is not recommended in the final multiple technology appraisal (MTA) guidance, clinicians in Scotland will be able to request the use of that medicine on a case-by-case basis for individual patients using the Peer Approved Clinical System (PACS) Tier Two process. National guidance explicitly states that Health Boards should not take account of the cost of medicines when considering applications using the PACS Tier Two system.